Advertisement

X-Linked Kidney Disorders in Women

  • Catherine Quinlan
    Affiliations
    Department of Nephrology, Royal Children's Hospital, Melbourne, Victoria, Australia

    Department of Kidney Regeneration, Murdoch Children's Research Institute, Melbourne, Victoria, Australia

    Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia
    Search for articles by this author
  • Michelle N. Rheault
    Correspondence
    Address reprint requests to Michelle N. Rheault, MD, Division of Pediatric Nephrology, University of Minnesota Masonic Children's Hospital, 2450 Riverside Ave, AO-201, Minneapolis, MN 55454.
    Affiliations
    Division of Pediatric Nephrology, Department of Pediatrics, University of Minnesota Masonic Children's Hospital, Minneapolis, MN
    Search for articles by this author

      Summary

      A number of genes that cause inherited kidney disorders reside on the X chromosome. Given that males have only a single active X chromosome, these disorders clinically manifest primarily in men and boys. However, phenotypes in female carriers of X-linked kidney conditions are becoming more and more recognized. This article reviews the biology of X inactivation as well as the kidney phenotype in women and girls with a number of X-linked kidney disorders including Alport syndrome, Fabry disease, nephrogenic diabetes insipidus, X-linked hypophosphatemic rickets, Dent disease, and Lowe syndrome.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Seminars in Nephrology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Richardson BJ
        • Czuppon AB
        • Sharman GB.
        Inheritance of glucose-6-phosphate dehydrogenase variation in kangaroos.
        Nat New Biol. 1971; 230: 154-155
        • Oikawa M
        • Inoue K
        • Shiura H
        • et al.
        Understanding the X chromosome inactivation cycle in mice: a comprehensive view provided by nuclear transfer.
        Epigenetics. 2014; 9: 204-211
        • Patrat C
        • Ouimette JF
        • Rougeulle C.
        X chromosome inactivation in human development.
        Development. 2020; (dev183095): 147
        • Petropoulos S
        • Edsgard D
        • Reinius B
        • et al.
        Single-cell RNA-seq reveals lineage and X chromosome dynamics in human preimplantation embryos.
        Cell. 2016; 167: 285
        • Migeon BR.
        X inactivation, female mosaicism, and sex differences in renal diseases.
        J Am Soc Nephrol. 2008; 19: 2052-2059
        • Trejo V
        • Derom C
        • Vlietinck R
        • et al.
        X chromosome inactivation patterns correlate with fetal-placental anatomy in monozygotic twin pairs: implications for immune relatedness and concordance for autoimmunity.
        Mol Med. 1994; 1: 62-70
        • Pinto LL
        • Vieira TA
        • Giugliani R
        • Schwartz IV.
        Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review.
        Orphanet J Rare Dis. 2010; 5: 14
        • Tukiainen T
        • Villani AC
        • Yen A
        • et al.
        Landscape of X chromosome inactivation across human tissues.
        Nature. 2017; 550: 244-248
        • Balaton BP
        • Dixon-McDougall T
        • Peeters SB
        • Brown CJ.
        The eXceptional nature of the X chromosome.
        Hum Mol Genet. 2018; 27 (R242-R249)
        • Franco B
        • Ballabio A.
        X-inactivation and human disease: X-linked dominant male-lethal disorders.
        Curr Opin Genet Dev. 2006; 16: 254-259
        • Hudson BG.
        The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family.
        J Am Soc Nephrol. 2004; 15: 2514-2527
        • Quinlan C
        • Rheault MN.
        Genetic basis of type IV collagen disorders of the kidney.
        Clin J Am Soc Nephrol. 2021; 16: 1101-1109
        • Savige J
        • Colville D
        • Rheault M
        • et al.
        Alport syndrome in women and girls.
        Clin J Am Soc Nephrol. 2016; 11: 1713-1720
        • Kashtan CE
        • Ding J
        • Garosi G
        • et al.
        Alport syndrome: a unified classification of genetic disorders of collagen IV alpha345: a position paper of the Alport Syndrome Classification Working Group.
        Kidney Int. 2018; 93: 1045-1051
        • Jais JP
        • Knebelmann B
        • Giatras I
        • et al.
        X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males.
        J Am Soc Nephrol. 2000; 11: 649-657
        • Yamamura T
        • Horinouchi T
        • Nagano C
        • et al.
        Genotype-phenotype correlation and the influence of the genotype on response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome.
        Kidney Int. 2020; 98: 1605-1614
        • Alport AC.
        Hereditary familial congenital haemorrhagic nephritis.
        Br Med J. 1927; 1: 504-506
        • Perkoff GT.
        Familial aspects of diffuse renal diseases.
        Annu Rev Med. 1964; 15: 115-124
        • Jais JP
        • Knebelmann B
        • Giatras I
        • et al.
        X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a “European Community Alport Syndrome Concerted Action” study.
        J Am Soc Nephrol. 2003; 14: 2603-2610
        • Yamamura T
        • Nozu K
        • Fu XJ
        • et al.
        Natural history and genotype-phenotype correlation in female X-linked Alport syndrome.
        Kidney Int Rep. 2017; 2: 850-855
        • Temme J
        • Peters F
        • Lange K
        • et al.
        Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations.
        Kidney Int. 2012; 81: 779-783
        • Takemon Y
        • Wright V
        • Davenport B
        • et al.
        Uncovering modifier genes of X-linked Alport syndrome using a novel multiparent mouse model.
        J Am Soc Nephrol. 2021; 32: 1961-1973
        • Guo C
        • Van Damme B
        • Vanrenterghem Y
        • Devriendt K
        • Cassiman JJ
        • Marynen P.
        Severe Alport phenotype in a woman with two missense mutations in the same COL4A5 gene and preponderant inactivation of the X chromosome carrying the normal allele.
        J Clin Invest. 1995; 95: 1832-1837
        • Iijima K
        • Nozu K
        • Kamei K
        • et al.
        Severe Alport syndrome in a young woman caused by a t(X;1)(q22.3;p36.32) balanced translocation.
        Pediatr Nephrol. 2010; 25: 2165-2170
        • Rheault MN
        • Kren SM
        • Hartich LA
        • et al.
        X-inactivation modifies disease severity in female carriers of murine X-linked Alport syndrome.
        Nephrol Dial Transplant. 2010; 25: 764-769
        • Nakanishi K
        • Iijima K
        • Kuroda N
        • et al.
        Comparison of alpha5(IV) collagen chain expression in skin with disease severity in women with X-linked Alport syndrome.
        J Am Soc Nephrol. 1998; 9: 1433-1440
        • Massella L
        • Onetti Muda A
        • Faraggiana T
        • Bette C
        • Renieri A
        • Rizzoni G
        Epidermal basement membrane alpha 5(IV) expression in females with Alport syndrome and severity of renal disease.
        Kidney Int. 2003; 64: 1787-1791
        • Bittel DC
        • Theodoro MF
        • Kibiryeva N
        • Fischer W
        • Talebizadeh Z
        • Butler MG.
        Comparison of X-chromosome inactivation patterns in multiple tissues from human females.
        J Med Genet. 2008; 45: 309-313
        • Wang Y
        • Zhang H
        • Ding J
        • Wang F.
        Correlation between mRNA expression level of the mutant COL4A5 gene and phenotypes of XLAS females.
        Exp Biol Med (Maywood). 2007; 232: 638-642
        • Vetrie D
        • Flinter F
        • Bobrow M
        • Harris A.
        X inactivation patterns in females with Alport's syndrome: a means of selecting against a deleterious gene?.
        J Med Genet. 1992; 29: 663-666
        • Kashtan CE
        • Gross O.
        Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020.
        Pediatr Nephrol. 2021; 36: 711-719
        • Gross O
        • Licht C
        • Anders HJ
        • et al.
        Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy.
        Kidney Int. 2012; 81: 494-501
      1. Di H, Zhang J, Gao E, et al. Dissecting the genotype-phenotype correlation of COL4A5 gene mutation and its response to renin-angiotensin-aldosterone system blockers in Chinese male patients with Alport syndrome. Nephrol Dial Transplant. Published online January 10, 2022. doi:10.1093/ndt/gfac002.

        • Stock J
        • Kuenanz J
        • Glonke N
        • et al.
        Prospective study on the potential of RAAS blockade to halt renal disease in Alport syndrome patients with heterozygous mutations.
        Pediatr Nephrol. 2017; 32: 131-137
        • Piccoli GB
        • Cabiddu G
        • Attini R
        • et al.
        Risk of adverse pregnancy outcomes in women with CKD.
        J Am Soc Nephrol. 2015; 26: 2011-2022
        • Hladunewich MA
        • Melamed N
        • Bramham K.
        Pregnancy across the spectrum of chronic kidney disease.
        Kidney Int. 2016; 89: 995-1007
        • Blom K
        • Odutayo A
        • Bramham K
        • Hladunewich MA.
        Pregnancy and glomerular disease: a systematic review of the literature with management guidelines.
        Clin J Am Soc Nephrol. 2017; 12: 1862-1872
        • Brunini F
        • Zaina B
        • Gianfreda D
        • et al.
        Alport syndrome and pregnancy: a case series and literature review.
        Arch Gynecol Obstet. 2018; 297: 1421-1431
        • Kashtan CE.
        Women with Alport syndrome: risks and rewards of kidney donation.
        Nephrol Dial Transplant. 2009; 24: 1369-1370
        • Gross O
        • Weber M
        • Fries JW
        • Muller GA.
        Living donor kidney transplantation from relatives with mild urinary abnormalities in Alport syndrome: long-term risk, benefit and outcome.
        Nephrol Dial Transplant. 2009; 24: 1626-1630
        • Hung CL
        • Wu YW
        • Lin CC
        • et al.
        2021 TSOC expert consensus on the clinical features, diagnosis, and clinical management of cardiac manifestations of Fabry disease.
        Acta Cardiol Sin. 2021; 37: 337-354
        • Zarate YA
        • Hopkin RJ.
        Fabry's disease.
        Lancet. 2008; 372: 1427-1435
        • Lenders M
        • Brand E.
        Precision medicine in Fabry disease.
        Nephrol Dial Transplant. 2021; 36: 14-23
        • Arends M
        • Wanner C
        • Hughes D
        • et al.
        Characterization of classical and nonclassical Fabry disease: a multicenter study.
        J Am Soc Nephrol. 2017; 28: 1631-1641
        • Wang RY
        • Lelis A
        • Mirocha J
        • Wilcox WR.
        Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life.
        Genet Med. 2007; 9: 34-45
        • Deegan PB
        • Baehner AF
        • Barba Romero MA
        • et al.
        Natural history of Fabry disease in females in the Fabry Outcome Survey.
        J Med Genet. 2006; 43: 347-352
        • Waldek S
        • Patel MR
        • Banikazemi M
        • Lemay R
        • Lee P.
        Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry.
        Genet Med. 2009; 11: 790-796
        • Ortiz A
        • Oliveira JP
        • Waldek S
        • et al.
        Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.
        Nephrol Dial Transplant. 2008; 23: 1600-1607
        • Ortiz A
        • Cianciaruso B
        • Cizmarik M
        • et al.
        End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.
        Nephrol Dial Transplant. 2010; 25: 769-775
        • Wilcox WR
        • Oliveira JP
        • Hopkin RJ
        • et al.
        Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.
        Mol Genet Metab. 2008; 93: 112-128
        • Ginsberg L.
        Nervous system manifestations of Fabry disease: data from FOS - the Fabry Outcome Survey.
        in: Mehta A Beck M Sunder-Plassmann G Fabry Disease: Perspectives From 5 Years of FOS. Oxford PharmaGenesis, 2006
        • Felis A
        • Whitlow M
        • Kraus A
        • Warnock DG
        • Wallace E.
        Current and investigational therapeutics for Fabry disease.
        Kidney Int Rep. 2020; 5: 407-413
        • Bichet DG
        • Bockenhauer D.
        Genetic forms of nephrogenic diabetes insipidus (NDI): Vasopressin receptor defect (X-linked) and aquaporin defect (autosomal recessive and dominant).
        Best Pract Res Clin Endocrinol Metab. 2016; 30: 263-276
        • Kinoshita K
        • Miura Y
        • Nagasaki H
        • Murase T
        • Bando Y
        • Oiso Y.
        A novel deletion mutation in the arginine vasopressin receptor 2 gene and skewed X chromosome inactivation in a female patient with congenital nephrogenic diabetes insipidus.
        J Endocrinol Invest. 2004; 27: 167-170
        • Sasaki S
        • Chiga M
        • Kikuchi E
        • Rai T
        • Uchida S.
        Hereditary nephrogenic diabetes insipidus in Japanese patients: analysis of 78 families and report of 22 new mutations in AVPR2 and AQP2.
        Clin Exp Nephrol. 2013; 17: 338-344
        • van Lieburg AF
        • Verdijk MA
        • Schoute F
        • et al.
        Clinical phenotype of nephrogenic diabetes insipidus in females heterozygous for a vasopressin type 2 receptor mutation.
        Hum Genet. 1995; 96: 70-78
        • Sarafrazi S
        • Daugherty SC
        • Miller N
        • et al.
        Novel PHEX gene locus-specific database: comprehensive characterization of vast number of variants associated with X-linked hypophosphatemia (XLH).
        Hum Mutat. 2022; 43: 143-157
        • Yamamoto A
        • Nakamura T
        • Ohata Y
        • Kubota T
        • Ozono K.
        Phenotypes of a family with XLH with a novel PHEX mutation.
        Hum Genome Var. 2020; 7: 8
        • Quinlan C
        • Guegan K
        • Offiah A
        • et al.
        Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment.
        Pediatr Nephrol. 2012; 27: 581-588
        • Haffner D
        • Emma F
        • Eastwood DM
        • et al.
        Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia.
        Nat Rev Nephrol. 2019; 15: 435-455
        • Morey M
        • Castro-Feijoo L
        • Barreiro J
        • et al.
        Genetic diagnosis of X-linked dominant hypophosphatemic rickets in a cohort study: tubular reabsorption of phosphate and 1,25(OH)2D serum levels are associated with PHEX mutation type.
        BMC Med Genet. 2011; 12: 116
        • Holm IA
        • Nelson AE
        • Robinson BG
        • et al.
        Mutational analysis and genotype-phenotype correlation of the PHEX gene in X-linked hypophosphatemic rickets.
        J Clin Endocrinol Metab. 2001; 86: 3889-3899
        • Gianesello L
        • Del Prete D
        • Anglani F
        • Calo LA.
        Genetics and phenotypic heterogeneity of Dent disease: the dark side of the moon.
        Hum Genet. 2021; 140: 401-421
        • Li F
        • Yue Z
        • Xu T
        • et al.
        Dent disease in Chinese children and findings from heterozygous mothers: phenotypic heterogeneity, fetal growth, and 10 novel mutations.
        J Pediatr. 2016; 174 (204-210.e1)
        • Ye Y
        • Wang J
        • Quan X
        • et al.
        Case report: a Chinese girl with dent disease 1 and turner syndrome due to a hemizygous CLCN5 gene mutation and Isochromosome (Xq).
        BMC Nephrol. 2020; 21: 171
        • syndrome Loi M.Lowe
        Orphanet J Rare Dis. 2006; 1: 16
        • De Matteis MA
        • Staiano L
        • Emma F
        • Devuyst O.
        The 5-phosphatase OCRL in Lowe syndrome and Dent disease 2.
        Nat Rev Nephrol. 2017; 13: 455-470
        • Sharma S
        • Skowronek A
        • Erdmann KS.
        The role of the Lowe syndrome protein OCRL in the endocytic pathway.
        Biol Chem. 2015; 396: 1293-1300
        • Festa BP
        • Berquez M
        • Gassama A
        • et al.
        OCRL deficiency impairs endolysosomal function in a humanized mouse model for Lowe syndrome and Dent disease.
        Hum Mol Genet. 2019; 28: 1931-1946
        • Wang R
        • Lei T
        • Fu F
        • et al.
        Application of chromosome microarray analysis in patients with unexplained developmental delay/intellectual disability in South China.
        Pediatr Neonatol. 2019; 60: 35-42
        • Yamamoto K
        • Hasegawa Y
        • Ohata Y
        • et al.
        Complete oculocerebrorenal phenotype of Lowe syndrome in a female patient with half reduction of inositol polyphosphate 5-phosphatase.
        CEN Case Rep. 2020; 9: 95-100